echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Ulus Travma Acil Cer: Comparison of analgesic consumption in patients with hemophilia and non-hemophilia during knee replacement

    Ulus Travma Acil Cer: Comparison of analgesic consumption in patients with hemophilia and non-hemophilia during knee replacement

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hemophilia is a rare inherited bleeding disorder that develops
    due to factor VIII or IX deficiency.
    Long-term complications of hemophilia, such as arthropathy, synovitis, and arthritis, can lead to the development of
    recurrent chronic pain.
    Therefore, pain is a key aspect of
    hemophilia.
    The gold standard treatment for end-stage hemophilic knee arthropathy is total knee replacement (TKA).

    A team of researchers conducted a study that hypothesized that hemophilia patients who took analgesics for a long time might experience higher levels of pain and use more opioids and non-opioids after knee replacement surgery, which causes severe postoperative pain
    .

    Figure: Research flowchart

    This retrospective study included patients with hemophilia and non-hemophilia TKA who underwent surgery under general anaesthesia from 2001 to 2020
    .
    All surgeries are performed
    by the same surgeon.
    Patients with missing files or additional surgery for TKA were excluded from
    the study.
    Data
    is obtained using files from the hospital registry, perioperative anesthesia forms, hematology forms, and discharge information.
    In this study, data from 82 patients were evaluated and their eligibility for the study investigated
    .
    Of these, 73 patients were included in the study
    .
    According to the diagnosis of hemophilia, it was divided into two groups: 36 cases in the hemophilia group and 37 cases
    in the non-hemophilia group.

    Table: Regression analysis

    In this retrospective study, they found that tramadol (p=0.
    002) and meperidine (p=0.
    003) were significantly higher
    in the hemophilia group in terms of consumption as analgesics after TKA.
    Pain that does not respond to analgesics is the most common indication for TKA, which is considered the gold standard treatment
    for end-stage hemophilic arthropathy in patients with hemophilia.
    Increased pain sensitivity in patients correlates
    with the severity of joint lesions.

    Based on this information, the researchers believe that acute postoperative pain management in hemophilia patients should be planned as individualized, multimodal prophylaxis, and preemptive analgesia
    .
    Regional anesthesia is also an option
    .
    Optimizing factor levels, femur, ischial and IPACK blocks under ultrasound guidance can be used for analgesia after total knee replacement in hemophilia patients to avoid increased opioid use and its side effects
    .

     

    Original source:

    Canbolat N, Dinç T, Koltka K, et al.
    Comparison of analgesic consumption of hemophilic and non-hemophilic patients in knee arthroplasty.
    Diz artroplastilerinde hemofilik ve non-hemofilik hastaların analjezik tüketimlerinin karşılaştırılması.
    Ulus Travma Acil Cerrahi Derg.
    2022; 28(11):1616-1621.
    doi:10.
    14744/tjtes.
    2021.
    47482

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.